LGND Ligand Pharmaceuticals Forecast, Technical & Fundamental Analysis

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +0.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 259 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 57 cases where LGND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LGND as a result. In 66 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for LGND turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

LGND broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.309) is normal, around the industry mean (3.498). P/E Ratio (30.167) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.267) is also within normal values, averaging (9.059). Dividend Yield (0.006) settles around the average of (130.981) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.